Initial clinical studies demonstrated potential benefits, including extended survival times and the induction of anti-tyrosinase antibodies, which suggest that a xeongenic tumor-associated antigen could serve as a target to generate clinically effective anti-tumor T-cell responses [24,25,26]. This evidence concerns the gene TYR and neoplasm.